drugset / Trial / NCT01719757

PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain

NCT01719757

Phase 4 Completed 359 enrolled Mundipharma Korea Ltd
NaSingle-groupOpen-labelTreatment

Summary

The aim of the study is to evaluate the efficacy of TARGIN administration as an analgesic to Korean patients treated with opioid analgesics for moderate-to-severe cancer pain under conditions of daily practice.

Timeline

Start
2012-07
Primary completion
2013-10
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxone Small molecule 5 mg Oral
Subject Naloxone Small molecule 10 mg Oral
Subject Oxycodone Other / unclassified 10 mg Oral
Subject Oxycodone Other / unclassified 20 mg Oral

Indications